Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-5: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
NCT04034173Phase 2Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (CRC), sponsored by Ludwig Maximilian University of Munich. Started Jul 2019; status: terminated.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04034173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034173.